Mankind Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Mankind Pharma Ltd (MNKI)
Mankind Pharma Ltd stock price live, this page displays BO MNKI stock exchange data. View the MNKI premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Mankind Pharma Ltd real time stock price chart below.
What Is the Mankind Pharma Ltd Stock Price Today?
The Mankind Pharma Ltd stock price today is 2 500,60.
What Is the Stock Symbol for Mankind Pharma Ltd?
The stock symbol for Mankind Pharma Ltd is "MNKI."
What Stock Exchange Does Mankind Pharma Ltd Trade On?
Mankind Pharma Ltd is listed and trades on the BSE stock exchange.
Is Mankind Pharma Ltd a Good Stock to Buy?
Determining whether Mankind Pharma Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MNKI quote. (ISIN: INE634S01028)
What Is the Mankind Pharma Ltd Stock Price Today?
The Mankind Pharma Ltd stock price today is 2 500,60.
What Is the Stock Symbol for Mankind Pharma Ltd?
The stock symbol for Mankind Pharma Ltd is "MNKI."
What Stock Exchange Does Mankind Pharma Ltd Trade On?
Mankind Pharma Ltd is listed and trades on the BSE stock exchange.
Is Mankind Pharma Ltd a Good Stock to Buy?
Determining whether Mankind Pharma Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MNKI quote. (ISIN: INE634S01028)
2,500.60
+198.60(+8.63%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2,358.30
2,530.00
52 wk Range
1,909.90
2,640.30
543904 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2,358.302,530.00
52 wk Range
1,909.902,640.30
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
543904 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high P/E ratio relative to near-term earnings growth
Mankind Pharma receives Investment Bank Analyst Rating Update- Investing.com
Pro
Mankind Pharma receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Mankind Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Mankind Pharma receives Investment Bank Analyst Rating Update- Investing.com
Pro- Mankind Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Mankind Pharma Ltd Earnings Call Summary for Q2/2027
- Mankind Pharma Q2 FY27 revenue rose 17.3% YoY to INR 4,338 crore; EBITDA up 27.2% to INR 1,175 crore; PAT surged 37.7% to INR 716 crore.
- EBITDA margin expanded 210 bps to 27.1%; PAT margin improved 240 bps to 16.5%, driven by operating leverage and better product mix.
- International revenue jumped 33% to INR 680 crore; chronic therapies outperformed broader market; volume growth accelerated to 6.7% from 4.7% in Q1.
- Management maintained FY27 EBITDA margin guidance at 25.5%-26.5%; lowered consumer healthcare outlook to high single-digit growth from earlier expectations.
- Stock rose 3.83% to $2,302 post-results; company targets raising chronic therapy share from 37.4% to 50% over next four to five years.
Last Updated: 2026/10/26, 14:42
Read Full TranscriptEarnings
Latest Release
Oct 26, 2026
EPS / Forecast
17,20 / 15,38
Revenue / Forecast
43,38B / 41,65B
Compare 543904 to Peers and Sector
Metrics to compare | 543904 | Peers Peers - average of corresponding metrics from companies closely matching 543904: GLENMARK, AJANTPHARM, ALKEM, AUROPHARMA, PFIZER | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship543904PeersSector |
|---|---|---|---|---|
P/E Ratio | 46.7x | 32.3x | −0.3x | |
PEG Ratio | 7.17 | 1.00 | 0.00 | |
Price/Book | 5.9x | 5.5x | 2.6x | |
Price / LTM Sales | 6.5x | 5.3x | 2.8x | |
Upside (Analyst Target) | 20.0% | 24.4% | 64.7% | |
Fair Value Upside | Unlock | 8.9% | 9.6% | Unlock |
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, urology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory, and other diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural and pet food products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Telmikind-Am, Gudcef, Glimestar-M, Candi Force, Nurokind-Gold, Telmikind-H, Telmikind, Nurokind-Lc, Nurokind Plus-Rf, Vomikind, Cefakind, Glizid-M, Monticope, and Gudcef-Cv brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Mankind Pharma (543904) Stock Price Today?
The Mankind Pharma stock price today is 2 500,60 INR.
What Stock Exchange Does Mankind Pharma Trade On?
Mankind Pharma is listed and trades on the Bombay Stock Exchange.
What Is the Stock Symbol for Mankind Pharma?
The stock symbol for Mankind Pharma is "543904."
What Is the Mankind Pharma Market Cap?
As of today, Mankind Pharma market cap is 954,96B INR.
What Is Mankind Pharma's Earnings Per Share (TTM)?
The Mankind Pharma EPS (TTM) is 54,33.
When Is the Next Mankind Pharma Earnings Date?
Mankind Pharma will release its next earnings report on Feb 03, 2027.
From a Technical Analysis Perspective, Is 543904 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Mankind Pharma Stock Split?
Mankind Pharma has split 0 times.
How Many Employees Does Mankind Pharma Have?
Mankind Pharma has 20451 employees.
What is the current trading status of Mankind Pharma (543904)?
As of Oct 27, 2026, Mankind Pharma (543904) is trading at a price of 2 500,60 INR, with a previous close of 2 500,60 INR. The stock has fluctuated within a day range of 2 358,30 INR to 2 530,00 INR, while its 52-week range spans from 1 909,90 INR to 2 640,30 INR.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.